Home › Companies › PEPG

PepGen

Market cap $269M 69.3M shares (10-Q, Nov 4, 2026) × $3.88 close Nov 17, 2026

Most recent annual filing: 2026-03-04

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. PGN-EDODM1 readout1H 2027PGN-EDODM1 readout, 1H 2027, material
  2. PGN-EDODM1 interimJan 2027PGN-EDODM1 interim, Jan 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

Technology platforms

EDO

Enhanced Delivery Oligonucleotide platform leveraging cell-penetrating peptides (CPPs) conjugated to oligonucleotide therapeutics (PPMOs) to optimize tissue penetration, cellular uptake, and nuclear delivery; focus on neuromuscular and neurologic diseases including myotonic dystrophy type 1

Targets: DMPK

Discontinued (1)

Capital (as filed)

Cash
$22.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$82.8M Sep 30, 2026
Operating cash flow
−$13.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$222M cash, runway 1H 2027 and 2H 2027 catalysts per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on PepGen, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch PepGen (PEPG) — Scientific Deep Dive for PGN-EDODM1 and the EDO Platform Differentiated chemistry and a $12B strategic precedent are real, but the 5 mg/kg MAD miss, FDA partial hold, kidney signal, late competitive position, and loaded $400M shelf make this a wait-and-watch into the 2H 2026 binary event.
  2. Speculative buy speculative UPDATE: PepGen (PEPG) - The DSMB Blinked First DSMB clearance for 10 mg/kg repeat dosing retired the kidney-signal trapdoor, dilution risk is no longer forced, and the binary readout now has a dated November catalyst — warranting a small speculative position.
  3. Buy core UPDATE: PepGen (PEPG) - The Coin Landed Heads, Then the Dilution Gun Fired The 10 mg/kg readout delivered 46.5% ITT-clean splicing correction with durable functional signals and manageable kidney safety, de-risking the core efficacy question and warranting an upgrade to Accumulate into the offering price.
  4. Buy core UPDATE: PepGen (PEPG) - Priced Above the Gap The offering priced above the pre-launch close at $5.00, confirming institutional demand; the story is unchanged but the expected discount never arrived, so accumulation is maintained with preference for pullbacks toward or below the deal price.
  5. Buy core UPDATE: PepGen (PEPG) - The Anchor Bought In RA Capital bought $43.1M at $5.00 and raised its stake to 30.5% while the stock fell 23% below the deal price, confirming anchor conviction and making the pullback the better entry the author had flagged.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (25)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)